The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

Inc42Asia

E2E Networks Swings To ₹73 Cr Profit In Q2, Revenue Jumps 411% YoY

October 16

Cloud infrastructure company E2E Networks’ operating revenue jumped 411% to ₹223.8 Cr in the second quarter of FY27 from ₹43.8 Cr in the year-ago quarter.

Funding & deals

Read at Inc42 ↗

One letter a week, starting soon.

Latest

E2E Networks Swings To ₹73 Cr Profit In Q2, Revenue Jumps 411% YoY

Related

AsiaRobot AI developer Ruoyu secures Pre-A funding led by Sunway Communication TechNode

AsiaAnt Group open-sources 560-billion-parameter Ling-3.1-flash AI model TechNode

AsiaSmartphone maker Transsion completes Hong Kong listing, raising about HKD 3.06 billion TechNode

AsiaDesktop manufacturing startup InfiMaker raises tens of millions of dollars in Pre-A+ funding TechNode

SiliconMercedes-Benz and NVIDIA Expand Strategic Partnership to Advance Safe Highly Automated Driving in the Next Decade NVIDIA Newsroom

AsiaAstraZeneca strikes $1.5b AI drug discovery deal with Insitro Tech in Asia